The Response of HIV-Associated Lymphadenopathic Kaposi Sarcoma to Highly Active Antiretroviral Therapy Evaluated by 18F-FDG PET/CT

被引：7

作者：

Mankia, Satveer K.

Miller, Robert F. ^{[2
]}

Edwards, Simon G. ^{[3
]}

Ramsay, Alan ^{[4
]}

Lee, Siow Ming ^{[1
]}

机构：

[1] Univ Coll London Hosp, Dept Oncol, London NW1 2PG, England

[2] UCL, Res Dept Infect & Populat Hlth, Ctr Sexual Hlth & HIV Res, London, England

[3] Camden Provider Serv, Mortimer Market Ctr, Dept Genitourinary Med, London, England

[4] UCL, Dept Histopathol, London, England

来源：

CLINICAL NUCLEAR MEDICINE | 2012年 / 37卷 / 07期

关键词：

Kaposi sarcoma; HIV; human herpes virus-8; PET/CT; HAART; chemotherapy; ERA;

D O I：

10.1097/RLU.0b013e3182485261

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The use of PET/CT for determining systemic Kaposi sarcoma (KS) involvement and treatment response remains to be formally assessed. Pretreatment human herpes virus-8 (HHV-8) viral load may predict clinical response of KS to therapy; however, its role in treatment monitoring and correlation with PET/CT findings is unknown. We report PET/CT findings and HHV-8 viral loads of a 46-year-old man with HIV-associated lymphadenopathic KS. After treatment with highly active antiretroviral therapy, an interval PET/CT showed partial response, despite an undetectable HHV-8 viral load. Chemotherapy was initiated, and the patient achieved a complete clinical, PET/CT, and virological response. PET/CT enabled monitoring of treatment response and led to changes in management.

引用

页码：692 / 693

页数：2

共 8 条

[1] 18F-Fluorodeoxyglucose positron emission tomography/computed tomography findings in a patient with human immunodeficiency virus-associated Castleman's disease and Kaposi sarcoma, disorders associated with human herpes virus 8 infection
Bertagna, Francesco
Biasiotto, Giorgio
Rodella, Rosita
Giubbini, Raffaele
Alavi, Abass
[J]. JAPANESE JOURNAL OF RADIOLOGY, 2010, 28 (03) : 231 - 234
[2] Evaluation of Plasma Human Herpesvirus 8 DNA as a Marker of Clinical Outcomes during Antiretroviral Therapy for AIDS-Related Kaposi Sarcoma in Zimbabwe
Borok, Margaret
Fiorillo, Suzanne
Gudza, Ivy
Putnam, Beverly
Ndemera, Buxton
White, Irene E.
Gwanzura, Lovemore
Schooley, Robert T.
Campbell, Thomas B.
[J]. CLINICAL INFECTIOUS DISEASES, 2010, 51 (03) : 342 - 349
[3] British HIV Association guidelines for HIV-associated malignancies 2008
Bower, M.
Collins, S.
Cottrill, C.
Cwynarski, K.
Montoto, S.
Nelson, M.
Nwokolo, N.
Powles, T.
Stebbing, J.
Wales, N.
Webb, A.
[J]. HIV MEDICINE, 2008, 9 (06) : 336 - 388
[4] El Amari EB, 2008, AIDS, V22, P1019, DOI 10.1097/QAD.0b013e3282fc9c03
[5] Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy
Gallafent, JH
Buskin, SE
De Turk, PB
Aboulafia, DM
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) : 1253 - 1260
[6] Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: Implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma
Krown, SE
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (03) : 399 - 402
[7] Whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography images before and after chemotherapy for Kaposi sarcoma and highly active antiretrovirus therapy
Morooka, Miyako
Ito, Kimiteru
Kubota, Kazuo
Minamimoto, Ryogo
Shida, Yoshitaka
Hasuo, Kanehiro
Ito, Tateki
Tasato, Daisuke
Honda, Haruhito
Teruya, Katsuji
Kikuchi, Yoshimi
Ohtomo, Kuni
[J]. JAPANESE JOURNAL OF RADIOLOGY, 2010, 28 (10) : 759 - 762
[8] Imaging of HIV-Associated Kaposi Sarcoma; F-18-FDG-PET/CT and In-111-Bevacizumabscintigraphy
van de Luijtgaarden, Addy
van der Ven, Andre
Leenders, William
Kaal, Suzanne
Flucke, Uta
Oyen, Wim
van der Graaf, Winette
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 54 (04) : 444 - 446

← 1 →